National HIV Behavioral Surveillance (NHBS) study of men who have sex with men in San Francisco, 2023 **Preliminary results**

02/20/2024



Venue Sampling for MSM cycle

- Venues identified through formative assessment
 - N=39 venues
- Total number of weeks recruiting = 25 weeks
 - Total months in the field = 6
- Total number of events = 81
 - An average of 81/6 = 13.5 events per month




Eligibility criteria


- 18 y/o +
- Resident of San Francisco or San Mateo counties
- Male sex at birth AND (identified as man or non-binary)
- (Female sex at birth or intersex at birth) AND identified as man
- Ever had sex with men
- Alert and capable of completing the survey in English or Spanish
- Had not participated in the study before



Eligibility participants



Age range of participants living with HIV, N=132



■ 18-29 ■ 30-39 ■ 40-49 ■ 50+

Demographic characteristics of NHBS-MSM sample, 2021 vs. 2023 (N=1050)

Characteristics	NHBS 2021 N=505	NHBS 2023 N=545	P-value
Sex at birth and gender identity MSM Male-nonbinary Transmen	505 (100) 	503 (92) 33 (6) 9 (2)	
Sexual orientation Heterosexual or "Straight" Gay Bisexual	2 (<1) 464 (92) 37 (7)	4 (1) 468 (88) 60 (11)	0.070
Age group 18-29 30-39 40-49 50-59 60+	101 (20) 138 (27) 93 (18) 110 (22) 63 (13)	110 (20) 154 (28) 104 (19) 113 (21) 64 (12)	0.982

Characteristics of NHBS-MSM sample, 2021 vs. 2023 (N=1050)


Characteristics	NHBS 2021 N=505	NHBS 2023 N=545	P-value
Race/ethnicity Asian/Native Hawaiian/Pacific Islander Black/African American White Hispanic/Latino Other	70 (14) 26 (5) 273 (54) 105 (21) 28 (6)	53 (10) 42 (8) 243 (45) 171 (32) 30 (6)	<0.001
Education High school or less than Some college Bachelor's degree Post graduate studies	31 (6) 103 (20) 207 (41) 164 (32)	67 (12) 154 (28) 210 (39) 114 (21)	<0.001


Characteristics of NHBS-MSM sample, 2021 vs. 2023 (N=1050)

Characteristics	NHBS 2021 N=505	NHBS 2023 N=545	P-value
Occupation			0.721
Full-time	317 (63)	331 (61)	
Part-time	41 (8)	46 (8)	
Student	12 (2)	11 (2)	
Retired	32 (6)	47 (9)	
Unable to work (due to health reason)	22 (4)	19 (3)	
Unemployed	64 (13)	77 (14)	
Other	17 (3)	14 (3)	
Income			0.958
<40k	142 (29)	153 (29)	
40k-99k	181 (36)	188 (35)	
>100k	175 (35)	189 (36)	
			-


Access to healthcare among MSM in San Francisco, NHBS 2021 vs. 2023 (N=1050)

Characteristics	NHBS 2021 N=505	NHBS 2023 N=545	P-value
Have health insurance No Yes	25 (5) 480 (95)	43 (8) 502 (92)	0.053
Had a usual source of care No Yes	35 (7) 470 (93)	60 (11) 485 (89)	0.021
Saw a healthcare provider, past 12 months No Yes	43 (9) 462 (91)	59 (11) 486 (89)	0.206
Provider offered HIV test, past 12 months (among HIV negative or unknown, N=825) No Yes	136 (33) 273 (67)	156 (37) 260 (63)	0.202






HIV care cascade trends




Demographic characteristics among MSM living with HIV, 2023 (N=545)

Characteristics	N=129 (%)	P-value
Sex at birth and gender identity MSM Male-nonbinary Transmen	125 (97) 4 (3) 0	0.060
Sexual orientation Heterosexual or "Straight" Gay Bisexual	0 (0) 116 (90) 10 (10)	0.203
Age group 18-29 30-39 40-49 50-59 60+	7 (5) 22 (17) 28 (22) 45 (35) 27 (21)	<0.001

Who are impacted by HIV in San Francisco?




MSM living with HIV 2021 vs. 2023: age group




Social Determinants among MSM living with HIV, 2023

Characteristics	N=129 (%)	P-value
Race/ethnicity Asian/Native Hawaiian/Pacific Islander Black/African American White Hispanic Other	2 (2) 19 (15) 55 (43) 40 (33) 10 (8)	<0.001
Education High school or less than Some college Bachelor's degree Post graduate studies	22 (17) 55 (43) 30 (23) 22 (2)	<0.001
Income <40k 40k-99k >100k	56 (43) 41 (32) 29 (22)	<0.001

Who are impacted by HIV in San Francisco?



MSM living with HIV 2021 vs. 2023: race/ethnicity



2021 2023


Who are impacted by HIV in San Francisco?






Who are impacted by HIV in San Francisco?






HIV testing by demographics in 2023, overall



HIV testing among participants not living with HIV, 2023 (N=416)

Characteristics	Did not get an HIV test N=83 (%)	Had an HIV test N=333 (%)	P-value	
Sex at birth and gender identity MSM Male-nonbinary Transmen	79 (21) 2 (7) 2 (22)	299 (79) 27 (93) 7 (78)	0.189	
Sexual orientation Heterosexual or "Straight" Gay Bisexual	3 (75) 67 (19) 7 (14)	1 (25) 285 (81) 43 (86)	0.011	
Age group 18-29 30-39 40-49 50-59 60+	9 (9) 21 (16) 13 (17) 20 (29) 20 (54)	94 (91) 111 (84) 63 (83) 48 (71) 17 (46)	<0.001	


HIV testing by social determinants, overall




HIV testing among participants not living with HIV, 2023 (N=416)

Characteristics	Did not get an HIV test N=83 (%)	Had an HIV test N=333 (%)	P-value	
Race/ethnicity Asian/Native Hawaiian/Pacific Islander Black/African American White Hispanic Other	12 (24) 4 (17) 37 (20) 27 (21) 2 (10)	39 (76) 19 (83) 151 (80) 104 (79) 18 (90)	0.774	
Education High school or less than Some college Bachelor's degree Post graduate studies	14 (31) 24 (24) 30 (17) 15 (16)	31 (69) 75 (76) 150 (83) 77 (84)	0.085	
Income <40k 40k-99k >100k	24 (25) 32 (22) 26 (16)	73 (75) 115 (78) 134 (84)	0.223	


<u>Not</u> tested for HIV in the past 12 months by race/ethnicity




<u>Not</u> tested for HIV test in the past 12 months by educational attainment




PrEP cascade, 2023



PrEP cascade by race/ethnicity, 2023




PrEP cascade 2021 vs. 2023




MSM 2021 MSM 2023

Currently on PrEP by race/ethnicity 2021 vs. 2023




Other HIV prevention engagement, past 12 months



Other HIV Prevention engagement among sexually active & HIV negative or unknown MSM, 2023 (N=379)

Preventive behaviors	Used condom N=75 (%)	Did not use condom N=304 (%)	P-value
Used PrEP No Yes	56 (75) 19 (25)	93 (31) <mark>211 (69)</mark>	<0.001
Used PrEP 2-1-1 No Yes	68 (91) 7 (9)	252 (83) 52 (17)	0.096
Used PEP No Yes	68 (92) 6 (8)	273 (90) 31 (10)	0.588




Interest in taking doxy-PEP among MSM, 2023

• *Out of 42 who were HIV negative or unknown HIV status and answered they are not at risk for STIs (as a reason for not taking Doxy-PEP), 7 were on PrEP (17%).



Preventive behaviors	N (%)
Interest in taking doxy-PEP (N=230)	125 (54)
Reasons against taking doxy-PEP (N=105) Not at risk for STIs Not enough information to make a decision Concern about side effects Fear of antibiotic drug resistance Already took too many medications Other	59 (56) 31 (30) 10 (10) 7 (7) 5 (5) 8 (8)

PrEP preferences among MSM, 2023



Daily oral PrEP


- Injectable PrEP every 2 months
- Injectable PrEP every 6 months
- PrEP implant 1-2 times a year

Awareness and interest in injectable PrEP among MSM, 2023

Preventive behaviors	N (%)
Heard of injectable PrEP (N=537) No Yes	181 (34) 356 (66)
Took injectable PrEP	5 (1)
Interest in taking long-acting PrEP every 2 months (asked among HIV negative or unknown, N=320) Very interested Somewhat interested Neutral Somewhat uninterested Very uninterested	129 (40) 77 (24) 20 (6) 22 (7) 72 (23)

Awareness and interest in injectable PrEP among MSM, 2023

Preventive behaviors	N (%)
 Reasons in favor of taking long-acting PrEP every 2 months (asked among HIV negative or unknown, N=377) I would not have to remember to take a pill every day Injections provide a longer duration of protection than taking a daily pill I would not have to worry about losing my pills or having them stolen Injections would be more discreet than taking pills Other 	262 (70) 120 (32) 53 (14) 34 (9) 19 (5)
Reasons against taking long-acting PrEP every 2 months (asked among HIV negative or unknown, N=377) Possible side effects associated with the injections (e.g., pain, swelling) It would be too hard to go to a clinical site for an injection every 2 months I do not want something injected into my body Once the injection is administered, it cannot be reversed immediately/PrEP will stay in my body for a long time Other	103 (27) 96 (25) 83 (22) 19 (5) 24 (6)



Reasons against taking MPOX vax among MSM, 2023

Preventive behaviors	N (%)
Reasons against receiving the Mpox vaccine (Jyneeos) (N=128)	
Not at risk for Mpox or not concerned about Mpox	66 (52)
Could not make an appointment	16 (13)
Not enough information to make a decision	15 (12)
Concern about side effects	11 (9)
Already took too many vaccines	9 (7)
Concerned about safety	8 (6)
Inconvenient (e.g., too far, time off from work, waiting time too long, too	8 (6)
busy)	
I am not eligible for the Mpox vaccine	5 (4)
I have a medical reason that makes me ineligible to get vaccinated (e.g., I	4 (3)
have had a severe allergy to vaccines in the past).	
Concerned about the vaccine being effective in preventing Mpox	2 (2)
Other	20 (16)
I am not eligible for the Mpox vaccine I have a medical reason that makes me ineligible to get vaccinated (e.g., I have had a severe allergy to vaccines in the past). Concerned about the vaccine being effective in preventing Mpox	4 (3) 2 (2)

In summary – Much progress but there is work to do

- Among 545 MSM participants, HIV prevalence was 24.4%.
- Almost all participants were aware of their HIV status
- Almost all participants living with HIV were on ART.
- More than 90% of MSM living with HIV were virally suppressed

- Racial disparities in HIV persist as almost half of Black/African American MSM were living with HIV while this group only comprised 8% of the overall sample.
- MSM in 30-39 age group were the least likely to report viral suppression
- Less than half of MSM participants were on PrEP last time they had sex.
- Black/African American MSM had the least discussions about PrEP with a provider and the lowest PrEP use among racial/ethnic groups
- PrEP use has declined over time
- PrEP persistence is a challenge





Thanks!

- Bow for organizing these data and developing slides for this presentations
- Moranda for stewarding us through the data cleaning process
- Robert and the summer and fall NHBS MSM data and data collection teams, especially!

Questions!